Description
Tesofensine (NS2330) is an orally bioavailable synthetic small molecule that simultaneously inhibits the dopamine transporter (DAT; IC50 6.5 nM), norepinephrine transporter (NET; IC50 1.7 nM), and serotonin transporter (SERT; IC50 11 nM), elevating synaptic concentrations of all three monoamines through balanced transporter inhibition. Its long plasma half-life of approximately 234 hours produces sustained steady-state monoamine transporter inhibition relevant to chronic CNS signaling research protocols. Originally investigated in clinical trials for Parkinson’s disease and multiple metabolic research programs, it provides a defined three-transporter reference compound for research where simultaneous DAT, NET, and SERT inhibition are the experimental variables.
Storage and Handling
Store in a cool, dry place away from heat, moisture, and direct light. Keep container tightly sealed when not in use. Tesofensine is stable under standard ambient storage conditions; refer to the lot-specific certificate of analysis for specific requirements.
Compliance Notice
Tesofensine capsules are for laboratory research use only. They are not for human or veterinary use and carry no therapeutic, diagnostic, or clinical indication. FDA has not evaluated this product. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.
